(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Mom warns of Christmas gift hazard as daughter recovers in hospital - 2Extraordinary Shows to Long distance race on a Plane
- 3Flu is rising rapidly, driven by a new variant. Here's what to know
- 4German finance minister sees advantages of smartphones in schools
- 5Top Fascinating Organic products: Which One Might You Want to Attempt?
- Manual for Tracking down Spending plan Agreeable Travel Objections
- Manual for Notorious Fragrances: Immortal Aromas
- 'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- 'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
- Step by step instructions to Advance the Eco-friendliness of Your Kona SUV
- Reviving Your Home with Nutritious Indoor Plants
- Manual for Tracking down One of a kind Store Inns
- A hunger for new experiences Narratives: Motivating Travel and Experience
